London · Delayed Price · Currency is GBP · Price in EUR Epigenomics AG Statistics
Total Valuation
Epigenomics AG has a market cap or net worth of GBP 688,253. The enterprise value is 9.95 million.
| Market Cap | 688,253 |
| Enterprise Value | 9.95M |
Important Dates
The next estimated earnings date is Tuesday, March 24, 2026.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 876,949 |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.21% |
| Shares Change (QoQ) | -0.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | 622,084 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 200.72 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.20 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.94
| Current Ratio | 21.94 |
| Quick Ratio | 21.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -3.80% |
| Return on Invested Capital (ROIC) | -6.28% |
| Return on Capital Employed (ROCE) | -6.14% |
| Revenue Per Employee | 1,143 |
| Profits Per Employee | -788,618 |
| Employee Count | 2 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.08% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -2.08% |
| 50-Day Moving Average | 197.61 |
| 200-Day Moving Average | 275.56 |
| Relative Strength Index (RSI) | 21.46 |
| Average Volume (20 Days) | 2,720 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Epigenomics AG had revenue of GBP 3,429 and -2.37 million in losses. Loss per share was -2.70.
| Revenue | 3,429 |
| Gross Profit | 3,429 |
| Operating Income | -622,322 |
| Pretax Income | -2.37M |
| Net Income | -2.37M |
| EBITDA | -1.19M |
| EBIT | -622,322 |
| Loss Per Share | -2.70 |
Balance Sheet
The company has 654,896 in cash and 9.76 million in debt, giving a net cash position of -9.10 million.
| Cash & Cash Equivalents | 654,896 |
| Total Debt | 9.76M |
| Net Cash | -9.10M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | 646,324 |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -18,148.79% |
| Pretax Margin | -68,995.42% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Epigenomics AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.21% |
| Shareholder Yield | -0.21% |
| Earnings Yield | -343.75% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 8, 2023. It was a reverse split with a ratio of 0.2.
| Last Split Date | Dec 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Epigenomics AG has an Altman Z-Score of -10.59 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.59 |
| Piotroski F-Score | 1 |